Compare PRVA & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRVA | HCM |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.3B |
| IPO Year | 2021 | 2015 |
| Metric | PRVA | HCM |
|---|---|---|
| Price | $20.40 | $12.83 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 12 | 1 |
| Target Price | ★ $31.17 | $13.75 |
| AVG Volume (30 Days) | ★ 990.2K | 85.3K |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.64 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $2,122,842,000.00 | N/A |
| Revenue This Year | $18.19 | $20.60 |
| Revenue Next Year | $10.72 | $15.62 |
| P/E Ratio | $226.89 | ★ $5.49 |
| Revenue Growth | ★ 22.26 | N/A |
| 52 Week Low | $19.53 | $9.77 |
| 52 Week High | $28.82 | $17.79 |
| Indicator | PRVA | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 27.73 | 57.52 |
| Support Level | $19.62 | $12.99 |
| Resistance Level | $23.99 | $15.22 |
| Average True Range (ATR) | 0.52 | 0.30 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 11.70 | 53.07 |
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.